Oral chemotherapy for hormone refractory prostate cancer: The University of Michigan experience

J. M. Kamradt, D. C. Smith, K. J. Pienta

Research output: Contribution to journalArticlepeer-review

Abstract

The use of oral chemotherapy for the treatment of malignant disease is expanding. The authors' experience with oral chemotherapy for hormone- refractory prostate cancer continues to grow. These therapies are well- tolerated and effective. Already, these regimens are being improved by hybridizing them with intravenous agents such as paclitaxel. Also, oral novel agents are being tested that may offer new options for the treatment of hormone-refractory prostate cancer.

Original languageEnglish (US)
Pages (from-to)333-340
Number of pages8
JournalUrologic Clinics of North America
Volume26
Issue number2
DOIs
StatePublished - 1999
Externally publishedYes

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Oral chemotherapy for hormone refractory prostate cancer: The University of Michigan experience'. Together they form a unique fingerprint.

Cite this